EUVIMEDEUVIMED entdecken
Crossref

Optimization of a Series of Novel 1 H -Pyrrolo[3,2- c ]pyridine-Based USP1 Inhibitors with Potent In Vivo Antitumor Activity

Tao Yang iD, Xue Cui, Qingyan Li, Yaxin Teng, Minghai Tang, Xinyu Zou, Xiaobo Cen iD, Lijuan Chen iD, Min Zhao iD, Linyu Yang, Zhuang Yang iD

Journal of Medicinal Chemistry · 2026

DOI: 10.1021/acs.jmedchem.6c01009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Tao Yang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Natural and Targeted Small Molecule Drugs, Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China H…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Pyridines, Ubiquitin-Specific Proteases, Pyrroles. Die Arbeit nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China, West China Hospital, Sichuan University, Natural Science Foundation of Sichuan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

USP1, a deubiquitinating enzyme critical for DNA damage repair, represents a promising therapeutic target for cancers. In this study, we employed scaffold hopping to design and synthesize a series of 1H-pyrrolo[3,2-c]pyridine-based USP1 inhibitors. Among these, the lead compound 38a displayed robust enzymatic and cellular potencies. 38a dose-dependently induced Ub-PCNA accumulation, triggered cell cycle arrest, and potently suppressed cell viability. Additionally, 38a synergized with olaparib in MDA-MB-463 cells. Uniquely, 38a effectively induced c-MYC downregulation. In vivo studies confirmed 38a’s favorable oral bioavailability. In the MDA-MB-436 xenograft model, the combination of 38a with olaparib exerted potent antitumor efficacy, with a tumor inhibition rate of 80.7%, and the antitumor activity of 38a stemmed from USP1 inhibition. Furthermore, in the DLBCL PDX model with high c-MYC expression, 38a demonstrated efficacy comparable to standard first-line therapies. Preliminary safety evaluation confirmed the safety profile of 38a. Taken together, 38a is a highly promising antitumor lead compound with great translational potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsPyridinesUbiquitin-Specific ProteasesPyrrolesHumansAnimalsMiceStructure-Activity RelationshipCell Line, TumorXenograft Model Antitumor AssaysFemaleMice, NudeCell ProliferationCell Survival

Substanzen

Antineoplastic AgentsPyridinesUSP1 protein, humanUbiquitin-Specific ProteasesPyrroles

Autor:innen und Institutionen

  • Laboratory of Natural and Targeted Small Molecule Drugs, Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan610041, China.
  • National Chengdu Center for Safety Evaluation of Drugs, West China Hospital, Sichuan University, Chengdu, Sichuan610041, China.
  • Department of Urology, Institute of Urology (Laboratory of Reconstructive Urology), West China Hospital, Sichuan University, Chengdu, Sichuan610041, China.

ORCID-Profile: Tao Yang, Xiaobo Cen, Lijuan Chen, Min Zhao, Zhuang Yang

Förderung

  • National Natural Science Foundation of China
  • West China Hospital, Sichuan University
  • Natural Science Foundation of Sichuan Province

Zitieren

APA

Yang, T., Cui, X., Li, Q., Teng, Y., Tang, M., Zou, X., Cen, X., Chen, L., Zhao, M., Yang, L., & Yang, Z. (2026). Optimization of a Series of Novel 1 H -Pyrrolo[3,2- c ]pyridine-Based USP1 Inhibitors with Potent In Vivo Antitumor Activity. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c01009

Vancouver

Yang T, Cui X, Li Q, Teng Y, Tang M, Zou X, et al. Optimization of a Series of Novel 1 H -Pyrrolo[3,2- c ]pyridine-Based USP1 Inhibitors with Potent In Vivo Antitumor Activity. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c01009

BibTeX
@article{Yang2026,
  author = {Yang, Tao and Cui, Xue and Li, Qingyan and Teng, Yaxin and Tang, Minghai and Zou, Xinyu and Cen, Xiaobo and Chen, Lijuan and Zhao, Min and Yang, Linyu and Yang, Zhuang},
  title = {Optimization of a Series of Novel 1 H -Pyrrolo[3,2- c ]pyridine-Based USP1 Inhibitors with Potent In Vivo Antitumor Activity},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  doi = {10.1021/acs.jmedchem.6c01009}
}
Kostenlos starten →